Terms: = Ovarian cancer AND FGFR1OP, FOP, 11116, ENSG00000213066
11 results:
1. Death anxiety predicts fear of cancer recurrence and progression in ovarian cancer patients over and above other cognitive factors.
Coutts-Bain D; Sharpe L; Russell H
J Behav Med; 2023 Dec; 46(6):1023-1031. PubMed ID: 37306857
[TBL] [Abstract] [Full Text] [Related]
2. Frizzled-3 suppression overcomes multidrug chemoresistance by Wnt/β-catenin signaling pathway inhibition in hepatocellular carcinoma cells.
Meng Z; Liu Q; Liu Y; Yang Y; Shao C; Zhang S
J Chemother; 2023 Nov; 35(7):653-661. PubMed ID: 36843499
[TBL] [Abstract] [Full Text] [Related]
3. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract] [Full Text] [Related]
4. circFBXO7/miR-96-5p/MTSS1 axis is an important regulator in the Wnt signaling pathway in ovarian cancer.
Wu M; Qiu Q; Zhou Q; Li J; Yang J; Zheng C; Luo A; Li X; Zhang H; Cheng X; Lu W; Liu P; Lu B; Lu Y
Mol Cancer; 2022 Jun; 21(1):137. PubMed ID: 35768865
[TBL] [Abstract] [Full Text] [Related]
5. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPfop).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract] [Full Text] [Related]
6. Are fear of cancer recurrence and fear of progression equivalent constructs?
Coutts-Bain D; Sharpe L; Pradhan P; Russell H; Heathcote LC; Costa D
Psychooncology; 2022 Aug; 31(8):1381-1389. PubMed ID: 35470502
[TBL] [Abstract] [Full Text] [Related]
7. Long non-coding RNA NRSN2-AS1 facilitates tumorigenesis and progression of ovarian cancer via miR-744-5p/PRKX axis.
Chen Q; Xie J; Yang Y
Biol Reprod; 2022 Mar; 106(3):526-539. PubMed ID: 34791059
[TBL] [Abstract] [Full Text] [Related]
8. OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Frangou E; Bertelli G; Love S; Mackean MJ; Glasspool RM; Fotopoulou C; Cook A; Nicum S; Lord R; Ferguson M; Roux RL; Martinez M; Butcher C; Hulbert-Williams N; Howells L; Blagden SP
Gynecol Oncol; 2021 Aug; 162(2):431-439. PubMed ID: 34059348
[TBL] [Abstract] [Full Text] [Related]
9. microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Signal; 2020 Feb; 66():109466. PubMed ID: 31706018
[TBL] [Abstract] [Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
Pavlov MJ; Ceranic MS; Latincic SM; Sabljak PV; Kecmanovic DM; Sugarbaker PH
Int J Hyperthermia; 2018 Aug; 34(5):564-569. PubMed ID: 28877609
[TBL] [Abstract] [Full Text] [Related]
11. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract] [Full Text] [Related]
